A variety of CPT code changes take effect in 2026, and many of them will make a direct impact on interventional cardiology. Arnold Seto, MD, spoke to Cardiovascular Business about these updates for a new video interview.

Mitral valve surgery can be especially challenging when patients present with a small mitral valve area. When it comes to M-TEER, however, treatment still appears to be both safe and effective.

The device, currently just a prototype, could be the first of its kind to gain FDA approval.

According to a new study of nearly 7,000 patients, type 1 and type 2 diabetes are both linked to significantly shorter life expectancies. The risk of sudden cardiac death appears to be highest for younger patients.

Interventional cardiology's second Match Day was a significant success. Due to a lack of candidates, however, dozens of fellowship positions remain unfilled. 

The results were shown in multiple posts on X. A clinical trial to prove the safety and efficacy of Elon Musk's brain implant is ongoing, with 12 people currently using the devices.

While patients with a weakened immune system are still more likely to die after TAVR than other patients, those deaths are largely not related to the procedure or any other cardiovascular issues. This new meta-analysis explored data from a variety of clinical trials.

Pope Leo XIV told interventional cardiologists their work “stands at the crossroads of science, compassion and ethical responsibility.” When they treat patients, he added, they are treating the heart “both physically and metaphorically, bringing relief to those who suffer.”